Natera's Signatera detects head and neck cancer recurrence median 4.3 months before imaging in study
NTRA•Natera said three peer-reviewed studies evaluated Signatera in head and neck cancer. Surveillance testing detected recurrence a median 4.3 months before imaging, while post-surgery testing identified patients likely to benefit from adjuvant chemotherapy.
1. Study findings
Natera announced three published, peer-reviewed studies evaluating its Signatera test in head and neck cancer. After surgery, testing identified patients likely to benefit from adjuvant chemotherapy, while patients who tested negative showed no improvement with chemotherapy. During surveillance, the test detected recurrence a median 4.3 months before imaging across HPV-positive and HPV-negative disease and outperformed clinical risk factors in predicting progression.
